Loading…
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $825M | $-331M | $-366M | $-26M | -99.4% | -1.6% | - |
| 2024 | $838M | $-60M | $-127M | $-38M | -18.2% | 11.2% | - |
| 2023 | $753M | $-197M | $-263M | $-184M | -33.6% | 11.0% | - |
| 2022 | $678M | $-85M | $-112M | $-152M | -12.6% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 678.40 | 753.20 | 837.60 | 824.50 |
| Cost Of Revenue | 202 | 236.20 | 252.20 | 247.90 |
| Gross Profit | 476.40 | 517 | 585.40 | 576.60 |
| Operating Expense | 600.10 | 661.60 | 673.40 | 644.40 |
| Operating Income | -123.70 | -144.60 | -88 | -67.80 |
| EBITDA | -84.70 | -197.40 | -59.50 | -330.90 |
| EBIT | -137.40 | -259.30 | -120.70 | -384.60 |
| Pretax Income | -140.60 | -262.20 | -123.50 | -395.10 |
| Tax Provision | -28.60 | 1.10 | 3.80 | -29.20 |
| Net Income | -112 | -263.30 | -127.30 | -365.90 |
| Net Income Common Stockholders | -112 | -263.30 | -127.30 | -365.90 |
| Total Expenses | 802.10 | 897.80 | 925.60 | 892.30 |
| Interest Expense | 3.20 | 2.90 | 2.80 | 10.50 |
| Interest Income | 2.60 | 2.50 | 1.70 | 1.80 |
| Research And Development | 85.40 | 88.70 | 113.40 | 106.80 |
| Selling General And Administration | 514.70 | 572.90 | 560 | 537.60 |
| Normalized EBITDA | -67.80 | -84.60 | -24 | -11.50 |
| Normalized Income | -98.54 | -174.19 | -99.25 | -70.14 |
| Basic EPS | -1.39 | -3.18 | -1.41 | -3.95 |
| Diluted EPS | -1.39 | -3.18 | -1.41 | -3.95 |
| Tax Effect Of Unusual Items | -3.44 | -23.69 | -7.46 | -23.64 |
| Tax Rate For Calcs | 0.20 | 0.21 | 0.21 | 0.07 |
| Total Unusual Items | -16.90 | -112.80 | -35.50 | -319.40 |
| Total Unusual Items Excluding Goodwill | -16.90 | -112.80 | -35.50 | -319.40 |
| Net Income From Continuing Operation Net Minority Interest | -112 | -263.30 | -127.30 | -365.90 |
| Reconciled Depreciation | 52.70 | 61.90 | 61.20 | 53.70 |
| Reconciled Cost Of Revenue | 202 | 236.20 | 252.20 | 247.90 |
| Net Interest Income | -0.60 | -0.40 | -1.10 | -8.70 |
| Net Income From Continuing And Discontinued Operation | -112 | -263.30 | -127.30 | -365.90 |
| Total Operating Income As Reported | -140.60 | -257.40 | -123.50 | -387.20 |
| Diluted Average Shares | 80.60 | 82.80 | 90.60 | 92.60 |
| Basic Average Shares | 80.60 | 82.80 | 90.60 | 92.60 |
| Diluted NI Availto Com Stockholders | -112 | -263.30 | -127.30 | -365.90 |
| Minority Interests | 0 | 0 | 0 | 0 |
| Net Income Including Noncontrolling Interests | -112 | -263.30 | -127.30 | -365.90 |
| Net Income Continuous Operations | -112 | -263.30 | -127.30 | -365.90 |
| Other Income Expense | -16.30 | -117.20 | -34.40 | -318.60 |
| Other Non Operating Income Expenses | 0.60 | -4.40 | 1.10 | 0.80 |
| Special Income Charges | -16.90 | -112.80 | -35.50 | -319.40 |
| Other Special Charges | 0 | 112.80 | -21.30 | 0 |
| Impairment Of Capital Assets | 16.90 | 0 | 56.80 | 319.40 |
| Net Non Operating Interest Income Expense | -0.60 | -0.40 | -1.10 | -8.70 |
| Interest Expense Non Operating | 3.20 | 2.90 | 2.80 | 10.50 |
| Interest Income Non Operating | 2.60 | 2.50 | 1.70 | 1.80 |
| Selling And Marketing Expense | 266.80 | 289.20 | 284.10 | 280.80 |
| General And Administrative Expense | 247.90 | 283.70 | 275.90 | 256.80 |
| Other Gand A | 247.90 | 283.70 | 275.90 | 256.80 |
| Operating Revenue | 678.40 | 753.20 | 837.60 | 824.50 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Myriad Genetics, Inc.this co. | MYGN | $442M | - | 1.19 | -99.4% | -2.56 |
| Larimar Therapeutics, Inc. | LRMR | $451M | - | 4.62 | -212.2% | -1.85 |
| Perspective Therapeutics, Inc. | CATX | $448M | - | 1.41 | -49.8% | -2.78 |
| Beta Bionics, Inc. | BBNX | $441M | - | 1.63 | -25.5% | -3.29 |
| AngioDynamics, Inc. | ANGO | $440M |
| - |
| 2.56 |
| -18.6% |
| -634.17 |
| Atea Pharmaceuticals, Inc. | AVIR | $435M | - | 1.54 | -57.5% | -0.73 |
| REGENXBIO Inc. | RGNX | $434M | - | 4.16 | -188.7% | -3.19 |
| Evolent Health, Inc. | EVH | $432M | - | 1.02 | -128.7% | 14.29 |
| Aura Biosciences, Inc. | AURA | $432M | - | 3.13 | -77.6% | -2.73 |
| Peer Median | - | - | 2.09 | -67.5% | -2.75 | |